1. Sarah Cannon Research Institute ASCO Presentation Summary

2. 2 ASCO: 28 of 41 Abstracts Selected for Presentation Consortium – 11 Abstracts Submitted; 7 Accepted for Presentation STUDY #:TITLE:PRESENTATION:POSTER SCHEDULE: BRE 46 (# 1032) Phase II Trial of Weekly Docetaxel, Vinorelbine, and Herceptin in the First-Line Treatment of Patients with Metastatic Breast Cancer and Overexpression of HER-2 (First Author: Dr. Nancy Peacock; Medical Monitor: Dr. John Hainsworth) Poster Discussion ; Poster 13 Tuesday, 6/3 Poster Display: 8:00 a.m.-12:00 p.m. E450b Discussion: 11:00 a.m.-12:00 p.m. E354a BRE 73 (# 603) Phase II Trial of Dose Dense Neo­adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced and/or Inflammatory Breast Cancer (First Author and Medical Monitor: Dr. Denise Yardley) General Poster Session ; Poster 14G Monday, 6/2 2:00-6:00 p.m. S Hall, A1 BRE 74 (# 1090) Phase II Trial of Docetaxel plus Imatinib Mesylate in Metastatic Breast Cancer (First Author: Dr. David Waterhouse; Medical Monitor: Dr. Denise Yardley) General Poster Session ; Poster 39A Monday, 6/2 2:00-6:00 p.m. S Hall, A1 BRE 83 (# 627) Phase II Study of Preoperative Bevacizumab and Trastuzumab Administered with ABI-007 and Carboplatin in HER2 Overexpressing Breast Cancer (First Author: Dr. Eric Raefsky; Medical Monitor: Dr. Denise Yardley) General Poster Session ; Poster 19E Monday, 6/2 2:00-6:00 p.m. S Hall, A1 GU 32 (# 5010) Phase II Trial of Bevacizumab and RAD001 (Everolimus) in the Treatment of Patients with Advanced Clear Cell Renal Carcinoma (First Author: Dr. R.C. Whorf; Medical Monitor: Dr. John Hainsworth) Clinical Science Symposium Presentation Saturday, 5/31 1:15-2:45 p.m. Presentation: 2:00 – 2:15 p.m. W375e LUN 110 (# 7554) Phase II Study of Irinotecan, Carboplatin, Bevacizumab and Radiation Therapy in the Treatment of Patients with Limited Stage Small Cell Lung Cancer (First Author and Medical Monitor: Dr. David Spigel) General Poster Session ; Poster 34D Sunday, 6/1 2:00-6:00 p.m. S Hall, A1 UNKPRI 19 (# 4607) Phase II Study of Paclitaxel/Carboplatin plus Bevacizumab/Erlotinib in the First Line Treatment of Patients with Carcinoma of Unknown Primary Site (First Author: Dr. Anthony Greco; Medical Monitor: Dr. John Hainsworth) General Poster Session ; Poster 41E Monday, 6/2 8:00 a.m. – 12:00 p.m. S Hall, A1

3. 3 Investigator-Sponsored Trials – 12 Abstracts Submitted; 7 Accepted for Presentation STUDY #:TITLE:PRESENTATION:POSTER SCHEDULE: BRE 97 (# 575) A Phase IIb, Randomized, Multicenter, Noncomparative Pilot Study of the Safety and Efficacy of Three Docetaxel-Based Chemotherapy Regimens plus Bevacizumab ± Trastuzumab for the Adjuvant Treatment of Patients with Node-Positive and High-Risk Node-Negative Breast Cancer (First Author: Dr. Lowell Hart; Medical Monitor: Dr. Denise Yardley) General Poster Session ; Poster 9B Monday, 6/2 2:00–6:00 p.m. S Hall, A1 LUN 136 (# 8079) Safety of Bevacizumab Therapy in Combination with Chemotherapy in Subjects with Non-Small Cell Lung Cancer (NSCLC) Treated on ATLAS (First Author: Dr. J. Polikoff; Medical Monitor: Dr. John Hainsworth) General Poster Session ; Poster 46B Sunday, 6/1 2:00–6:00 p.m. S Hall, A1 LUN 148 (# 8029) Efficacy and Safety of AZD6244 (ARRY-142886) as Second/Third-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) (First Author: Dr. V. Tzekova; Medical Monitor: Dr. John Hainsworth) Poster Discussion ; Poster 10 Monday, 6/2 Poster Display: 8:00 a.m.–12:00 p.m. W375e Lobby Discussion: 12:00–1:00 p.m. GU 31 (# 5045) Safety and Efficacy of Sorafenib in Early Patients Greater than or Equal to 65 Years: A Subset Analysis From the Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program in North America (First Author: Dr. R.M. Bukowski; Medical Monitor: Dr. John Hainsworth) Poster Discussion ; Poster 17 Sunday, 6/1 Poster Display: 8:00 a.m.-12:00p.m. W375e Lobby Discussion: 12:00-1:00 p.m. LYM 50 (# 8539) A Phase I-II Trial of the Kinesin Spindle Protein (KSP) Inhibitor SB-743921 on Days 1 and 15 Every 28 Days in Non-Hodgkin or Hodgkin Lymphoma (First Author: Dr. O. O’Connor; Medical Monitor: Dr. John Hainsworth) Poster Discussion ; Poster 14 Tuesday, 6/3 Poster Display: 8:00 a.m.-12:00 p.m. E450a Discussion: 12:00-1:00 p.m. AML 01 (# 7051) A Double-Blind Placebo-Controlled Randomized Phase III Study of High Dose Continuous Infusion Cytosine Arabinoside (araC) with or without VNP40101M (Cloretazine®) in Patients with First Relapse of Acute Myeloid Leukemia (AML) General Poster Session ; Poster 38E Saturday, 5/31 8:00 a.m. – 12:00 p.m. S Hall, A1 AML 03 (# 7026) A Phase II Study of VNP40101M (Cloretazine®) in Elderly Patients with De Novo Poor Risk Acute Myelogenous Leukemia (AML) Poster Discussion ; Poster 15 Monday, 6/2 Poster Display: 2:00-6:00 p.m. E450a Discussion: 5:00-6:00 p.m., E354a ASCO: 28 of 41 Abstracts Selected for Presentation

4. 4 DDU Trials – 18 Abstracts Submitted; 14 Accepted for Presentation STUDY #:TITLE:PRESENTATION:POSTER SCHEDULE: GI 88 (# 4112) Axitinib in combination with chemotherapy: a phase I study in patients with solid tumors (V.V. Abhyankar) General Poster Session ; Poster 16E Monday, 6/2 8:00 a.m.-12:00 p.m. S Hall, A1 REFMAL 63 (# 3023) Phase I experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenocarcinoma (N. Lewis) Poster Discussion ; Poster 12 Friday, 5/30 Poster Display: 2:00-6:00 p.m. W375e Lobby Discussion: 5:00-6:00 p.m. W375a Lobby REFMAL 64 (# 2520) Phase I study of the pan aurora kinases inhibitor PHA-739358 administered as a 24 h infusion without/with G-CSF in a 14-day cycle in patients with advanced solid tumors (R. Cohen) Poster Discussion ; Poster 10 Monday, 6/2 Poster Display: 2:00-6:00 p.m. W375e Lobby Discussion: 5:00-6:00 p.m. W375a Lobby REFMAL 71 (# 3562) Tolerability/safety of sunitinib (SU) on schedule 2/1 in combination with capecitabine (C) in patients (pts) with advanced solid tumors (STs): a phase I dose-finding study (E.G. Chiorean) General Poster Session ; Poster 24A Sunday, 6/1 2:00-6:00 p.m. S Hall, A1 REFMAL 79 (# 3534) Phase I clinical, pharmacokinetic and pharmacodynamic evaluation of PF-00562271 targeting focal adhesion kinase in patients with advanced solid tumors (L.L. Siu) Poster Discussion ; Poster 11 Saturday, 5/31 12:00-1:00 p.m. W375a Lobby REFMAL 93 (# 1028) Phase I study of trastuzumab-DM1, first-in-class HER2 antibody-drug conjugate, in pts. with advanced HER2+ breast cancer (M. Beeram) Poster Discussion ; Poster 9 Tuesday, 6/3 Poster Display: 8:00 a.m.-12:00 p.m. E450b Discussion: 11:00 a.m.-12:00 p.m. E354a REFMAL 93 (# 1029) Phase I study of weekly dosing of trastuzumab-DM1 in patients with advanced HER2+breast cancer (S. N. Holden) Poster Discussion ; Poster 10 Tuesday, 6/3 11:00 a.m.-12:00 p.m. E354a ASCO: 28 of 41 Abstracts Selected for Presentation

5. 5 DDU Trials (Contd.) – 18 Abstracts Submitted; 14 Accepted for Presentation STUDY #:TITLE:PRESENTATION:POSTER SCHEDULE: REFMAL 95 (# 3552) Phase I study of the safety, tolerability, and pharmacokinetics of weekly paclitaxel administered in combination with pazopanib (A. R. Tan) General Poster Session; Poster 22G Sunday, 6/1 2:00-6:00 p.m. S Hall, A1 REFMAL 99 (# 2567) Phase I trial of romidepsin in combination with gemcitabine in patients with pancreatic and other advanced solid tumors (H. H. Doss) General Poster Session; Poster 12G Sunday, 6/1 2:00-6:00 p.m. S Hall, A1 REFMAL 100 (# 2517) Phase I accelerated dose-escalation, pharmacokinetic and pharmacodynamic study of PF-03814735, an oral aurora kinase inhibitor, in patients with advanced solid tumors: preliminary results (S. F. Jones) Poster Discussion ; Poster 7 Monday, 6/2 Poster Display: 2:00-6:00 p.m. W375e Lobby Discussion: 5:00-6:00 p.m. W375a Lobby REFMAL 102 (# 8051) Phase 1/2 study investigating the combination of RAD001 and erlotinib as 2nd and 3rd line therapy in patients with advanced non-small cell lung cancer previously treated with chemotherapy: Phase 1 results (V. Papadimitrakopoulou) General Poster Session ; Poster 42F Sunday, 6/1 2:00-6:00 p.m. S Hall, A1 REFMAL 104 (# 3538) Phase I trial of LBY135, a monoclonal antibody agonist to DR5, alone and in combination with capecitabine in advanced solid tumors (S. Sharma) Poster Discussion ; Poster 15 Saturday, 5/31 12:00-1:00 p.m. W375a Lobby REFMAL 106 (# 2501) Clinical, pharmacokinetic, pharmacodynamic findings in a Phase I trial of weekly intravenous AZD4877 in patients with refractory solid tumors (J. R. Infante) Clinical Science Symposium Monday, 6/2 1:15-2:45 p.m. W375a Presentation: 1:45-2:00 p.m. REFMAL 109 (# 2538) Phase I dose escalation study of NK012 (H. A. Burris) General Poster Session; Poster 9B Sunday, 6/1 2:00-6:00 p.m. S Hall, A1 ASCO: 28 of 41 Abstracts Selected for Presentation